MYGN
NASDAQ
$5.92
Myriad Genetics Inc (MYGN)
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Sector:
Healthcare
Industry:
Diagnostics & Research
Hold
Target: $6.25 (+5.57%)
Market Cap
$596M
Revenue 5Y CAGR
+38.33%
Free Cash Flow Yield
0.40%
Beta (5Y)
1.06
Price Chart
Valuation
Market Cap$596M
Forward P/E54.05
P/S1.02
P/B1.65
Profitability
Total Revenue (TTM)$829M
Gross Profit (TTM)$379M
EBITDA-$337M
Profit Margin-17%
Operating Margin-15.3%
EPS-$4.29
Financial Health
Debt-to-Equity35.7%
Free Cash Flow Yield0.40%
Growth & Risk
Revenue 5Y CAGR+38.33%
FCF 5Y CAGR-47.35%
Beta (5Y)1.06
Sharpe Ratio0.58